| Popis: |
Yi-Sheng Liu,1 Pi-Yi Chang,2 Po-Chin Liang,3 Ming-Ching Ou,4 Jen-I Hwang,5,6 Chien-Hung Chen7,8 1Department of Medical Imaging, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; 2Department of Radiology, Taichung Veterans General Hospital, Taichung City, Taiwan; 3Department of Radiology, National Taiwan University Hospital, Taipei City, Taiwan; 4Department of Diagnostic Radiology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; 5Department of Medical Imaging, Tungs’ Taichung MetroHarbor Hospital, Taichung City, Taiwan; 6Department of Radiology, School of Medicine, National Defense Medical Center, Taipei City, Taiwan; 7Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Douliu City, Yunlin County, Taiwan; 8Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, TaiwanCorrespondence: Chien-Hung Chen, Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, No. 579, Sec. 2, Yunlin Road, Douliu City, Yunlin County, 640, Taiwan, Tel +886-2-23123456 ext. 65923, Fax +886-2-23819723, Email chenhcc@ntu.edu.twPurpose: The aim of this retrospective study was to evaluate the safety and efficacy of patients with hepatocellular carcinoma treated with drug-eluting bead with doxorubicin transarterial chemoembolization (DEBDOX-TACE) in Taiwan.Patients and Methods: We retrospectively investigated 630 hepatocellular carcinoma patients who underwent DEBDOX-TACE in multiple institutions from 2011 to 2016 in Taiwan. Tumor response was assessed per modified response evaluation criteria in solid tumors, overall survival, and safety.Results: This study included 630 patients who underwent DEBDOX-TACE, participants’ mean age was 66 years, 68.1% males and 15.6% females. The mean doxorubicin dose administered via DEBDOX-TACE was 56 mg. Complete and partial response rates were 14.6% and 49.2%, respectively, with a disease control rate of 84.6%. The median overall survival was 29.2 months. The most common post-embolization symptom was abdominal pain (22.4%). No hepatic encephalopathy and no procedure-related death were found.Conclusion: Real-world data from Taiwan demonstrated that DEBDOX-TACE for hepatocellular carcinoma can achieve high tumor response rate with low adverse events.Keywords: chemoembolization, DEBDOX, doxorubicin, liver cancer |
